[go: up one dir, main page]

TW200700415A - New salt and polymorphs of the dpp-iv inhibitor - Google Patents

New salt and polymorphs of the dpp-iv inhibitor

Info

Publication number
TW200700415A
TW200700415A TW095109702A TW95109702A TW200700415A TW 200700415 A TW200700415 A TW 200700415A TW 095109702 A TW095109702 A TW 095109702A TW 95109702 A TW95109702 A TW 95109702A TW 200700415 A TW200700415 A TW 200700415A
Authority
TW
Taiwan
Prior art keywords
dpp
polymorphs
inhibitor
new salt
compound
Prior art date
Application number
TW095109702A
Other languages
English (en)
Inventor
Stefan Abrecht
Andre Gerard Bubendorf
Stephan Goetzoe
Olaf Grassmann
Francois Montavon
Regina Moog
Franziska Rohrer
Armin Ruf
Michelangelo Scalone
Urs Schwitter
Shaoning Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW200700415A publication Critical patent/TW200700415A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW095109702A 2005-03-22 2006-03-21 New salt and polymorphs of the dpp-iv inhibitor TW200700415A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05102251 2005-03-22

Publications (1)

Publication Number Publication Date
TW200700415A true TW200700415A (en) 2007-01-01

Family

ID=36406081

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095109702A TW200700415A (en) 2005-03-22 2006-03-21 New salt and polymorphs of the dpp-iv inhibitor

Country Status (17)

Country Link
US (1) US7772264B2 (zh)
EP (1) EP1888571A2 (zh)
JP (1) JP5043825B2 (zh)
KR (1) KR20070113305A (zh)
CN (1) CN101146801A (zh)
AR (1) AR055570A1 (zh)
AU (1) AU2006226447B2 (zh)
BR (1) BRPI0609580A2 (zh)
CA (1) CA2600203C (zh)
DO (1) DOP2006000066A (zh)
GT (1) GT200600125A (zh)
IL (1) IL185768A0 (zh)
MX (1) MX2007011546A (zh)
PA (1) PA8666701A1 (zh)
PE (1) PE20061109A1 (zh)
TW (1) TW200700415A (zh)
WO (1) WO2006100181A2 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en) 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
CZ2008512A3 (cs) 2008-08-26 2010-03-10 Zentiva, A. S Zpusob prípravy vysoce cistého vildagliptinu
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103787944A (zh) * 2012-11-01 2014-05-14 天津药物研究院 1-(2-氯乙酰基)-2-(s)-腈基吡咯烷的制备方法
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN104262227B (zh) * 2014-09-16 2018-09-18 东北制药集团股份有限公司 一种制备(s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的方法
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN106699627A (zh) * 2016-12-29 2017-05-24 青岛黄海制药有限责任公司 一种多相复式非连续生产法制备1‑(2‑氯乙酰基)‑2‑(s)‑氰基吡咯烷的方法
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07247246A (ja) * 1994-03-09 1995-09-26 Daicel Chem Ind Ltd 1−フェニル−3−ブチン誘導体とその製造方法
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
PT921125E (pt) * 1997-12-05 2002-06-28 Hoffmann La Roche Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
DE19755436A1 (de) 1997-12-13 1999-06-24 Beiersdorf Ag Verfahren zur zumindest partiellen direkten Beschichtung eines dehnfähigen Trägermaterials mit einer Haftklebemasse
ES2211053T3 (es) * 1998-03-30 2004-07-01 Japan Tobacco Inc. Procedimiento para producir un compuesto de isooxazolidindiona.
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US6673815B2 (en) * 2001-11-06 2004-01-06 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CN1310885C (zh) * 2002-08-29 2007-04-18 大正制药株式会社 4-氟-2-氰基吡咯烷衍生物苯磺酸盐
GB0313661D0 (en) * 2003-06-13 2003-07-16 Avecia Ltd Process

Also Published As

Publication number Publication date
WO2006100181A2 (en) 2006-09-28
JP2008534470A (ja) 2008-08-28
US7772264B2 (en) 2010-08-10
DOP2006000066A (es) 2006-09-30
GT200600125A (es) 2007-03-16
IL185768A0 (en) 2008-01-06
AU2006226447B2 (en) 2009-07-16
BRPI0609580A2 (pt) 2010-04-20
US20060217428A1 (en) 2006-09-28
EP1888571A2 (en) 2008-02-20
CA2600203C (en) 2012-12-04
KR20070113305A (ko) 2007-11-28
CA2600203A1 (en) 2006-09-28
PA8666701A1 (es) 2006-12-07
JP5043825B2 (ja) 2012-10-10
AU2006226447A1 (en) 2006-09-28
WO2006100181A3 (en) 2006-11-30
CN101146801A (zh) 2008-03-19
AR055570A1 (es) 2007-08-22
PE20061109A1 (es) 2006-10-13
MX2007011546A (es) 2007-10-19

Similar Documents

Publication Publication Date Title
TW200700415A (en) New salt and polymorphs of the dpp-iv inhibitor
ATE482947T1 (de) Neues salz und polymorph des dpp-iv-hemmers
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
EP2190428A4 (en) HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
IL187740A0 (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
JO2870B1 (en) Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
IL187741A0 (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
ZA200704154B (en) Substituted benzoquinolizines as DPP-IV inhibitors for the treatment of diabetes
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
MY146506A (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
WO2007041077A3 (en) Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2007011848A (es) Antagonistas del receptor de procineticina i.
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
WO2007137098A3 (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar
TW200728258A (en) Novel compounds
WO2007041112A3 (en) Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes